NCT01789723View on ClinicalTrials.gov

Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn

PHASE1WithdrawnINTERVENTIONAL

Timeline

Start Date

March 31, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Non Hodgkin's Lymphoma

Interventions

DRUG

Fusilev

Fusilev will be administered by IV push (3-5 minutes) at a dose of 5 mg/m2. Fusilev administration, QID or BID will start 24 ± 3 hours after Folotyn administration depending on the dose cohort.

DRUG

Folotyn

A cycle of Folotyn treatment is 7 weeks, 6 weeks of treatment followed by 1 week of rest.